Brian C Baumann1, Walter R Bosch2, Amit Bahl3, Alison J Birtle4, Rodney H Breau5, Amarnath Challapalli3, Albert J Chang6, Ananya Choudhury7, Sia Daneshmand8, Ali El-Gayed9, Adam Feldman10, Steven E Finkelstein11, Thomas J Guzzo1, Serena Hilman3, Ashesh Jani12, S Bruce Malkowicz1, Constantine A Mantz13, Viraj Master12, Anita V Mitra14, Vedang Murthy15, Sima P Porten6, Pierre M Richaud16, Paul Sargos16, Jason A Efstathiou10, Libni J Eapen5, John P Christodouleas17. 1. Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania. 2. Washington University in St. Louis, St. Louis, Missouri. 3. University Hospitals Bristol NHS Foundation Trust, Bristol, United Kingdom. 4. Royal Preston Hospital, Preston, United Kingdom. 5. University of Ottawa, Ottawa, Ontario, Canada. 6. University of California San Francisco, San Francisco, California. 7. Department of Clinical Oncology, The Christie NHS Foundation Trust, Manchester, United Kingdom; The University of Manchester, Manchester Academic Heath Science Centre, Manchester, United Kingdom. 8. University of Southern California, Los Angeles, California. 9. Saskatoon Cancer Centre, Saskatoon, Canada. 10. Massachusetts General Hospital, Boston, Massachusetts. 11. Cancer Treatment Centers of America, Tulsa, Oklahoma. 12. Emory University, Atlanta, Georgia. 13. 21(st) Century Oncology, Scottsdale, Arizona; 21st Century Oncology, Fort Myers, Florida. 14. University College London Hospital, London, United Kingdom. 15. Tata Memorial Center, Mumbai, India. 16. Institut Bergonié, Bordeaux, France. 17. Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania. Electronic address: christojo@uphs.upenn.edu.
Abstract
PURPOSE: To develop multi-institutional consensus clinical target volumes (CTVs) and organs at risk (OARs) for male and female bladder cancer patients undergoing adjuvant radiation therapy (RT) in clinical trials. METHODS AND MATERIALS: We convened a multidisciplinary group of bladder cancer specialists from 15 centers and 5 countries. Six radiation oncologists and 7 urologists participated in the development of the initial contours. The group proposed initial language for the CTVs and OARs, and each radiation oncologist contoured them on computed tomography scans of a male and female cystectomy patient with input from ≥1 urologist. On the basis of the initial contouring, the group updated its CTV and OAR descriptions. The cystectomy bed, the area of greatest controversy, was contoured by another 6 radiation oncologists, and the cystectomy bed contouring language was again updated. To determine whether the revised language produced consistent contours, CTVs and OARs were redrawn by 6 additional radiation oncologists. We evaluated their contours for level of agreement using the Landis-Koch interpretation of the κ statistic. RESULTS: The group proposed that patients at elevated risk for local-regional failure with negative margins should be treated to the pelvic nodes alone (internal/external iliac, distal common iliac, obturator, and presacral), whereas patients with positive margins should be treated to the pelvic nodes and cystectomy bed. Proposed OARs included the rectum, bowel space, bone marrow, and urinary diversion. Consensus language describing the CTVs and OARs was developed and externally validated. The revised instructions were found to produce consistent contours. CONCLUSIONS: Consensus descriptions of CTVs and OARs were successfully developed and can be used in clinical trials of adjuvant radiation therapy for bladder cancer.
PURPOSE: To develop multi-institutional consensus clinical target volumes (CTVs) and organs at risk (OARs) for male and female bladder cancerpatients undergoing adjuvant radiation therapy (RT) in clinical trials. METHODS AND MATERIALS: We convened a multidisciplinary group of bladder cancer specialists from 15 centers and 5 countries. Six radiation oncologists and 7 urologists participated in the development of the initial contours. The group proposed initial language for the CTVs and OARs, and each radiation oncologist contoured them on computed tomography scans of a male and female cystectomy patient with input from ≥1 urologist. On the basis of the initial contouring, the group updated its CTV and OAR descriptions. The cystectomy bed, the area of greatest controversy, was contoured by another 6 radiation oncologists, and the cystectomy bed contouring language was again updated. To determine whether the revised language produced consistent contours, CTVs and OARs were redrawn by 6 additional radiation oncologists. We evaluated their contours for level of agreement using the Landis-Koch interpretation of the κ statistic. RESULTS: The group proposed that patients at elevated risk for local-regional failure with negative margins should be treated to the pelvic nodes alone (internal/external iliac, distal common iliac, obturator, and presacral), whereas patients with positive margins should be treated to the pelvic nodes and cystectomy bed. Proposed OARs included the rectum, bowel space, bone marrow, and urinary diversion. Consensus language describing the CTVs and OARs was developed and externally validated. The revised instructions were found to produce consistent contours. CONCLUSIONS: Consensus descriptions of CTVs and OARs were successfully developed and can be used in clinical trials of adjuvant radiation therapy for bladder cancer.
Authors: Michael Froehner; Vladimir Novotny; Manfred P Wirth; Sabine Brookman-May; Atiqullah Aziz; Matthias May Journal: Cancer Date: 2014-07-12 Impact factor: 6.860
Authors: John P Christodouleas; Brian C Baumann; Jiwei He; Wei-Ting Hwang; Kai N Tucker; Justin E Bekelman; Catherine M Tangen; Seth P Lerner; Thomas J Guzzo; S Bruce Malkowicz; Harry Herr Journal: Cancer Date: 2014-01-03 Impact factor: 6.860
Authors: Brian C Baumann; Thomas J Guzzo; Jiwei He; David J Vaughn; Stephen M Keefe; Neha Vapiwala; Curtiland Deville; Justin E Bekelman; Kai Tucker; Wei-Ting Hwang; S Bruce Malkowicz; John P Christodouleas Journal: Int J Radiat Oncol Biol Phys Date: 2012-05-30 Impact factor: 7.038
Authors: Brian C Baumann; Kate Noa; E Paul Wileyto; Justin E Bekelman; Curtiland Deville; Neha Vapiwala; Maura Kirk; Stefan Both; Derek Dolney; Ali Kassaee; John P Christodouleas Journal: Med Dosim Date: 2015-08-29 Impact factor: 1.482
Authors: Colleen A F Lawton; Jeff Michalski; Issam El-Naqa; Mark K Buyyounouski; W Robert Lee; Cynthia Menard; Elizabeth O'Meara; Seth A Rosenthal; Mark Ritter; Michael Seider Journal: Int J Radiat Oncol Biol Phys Date: 2008-10-22 Impact factor: 7.038
Authors: Mohamed S Zaghloul; John P Christodouleas; Andrew Smith; Ahmed Abdallah; Hany William; Hussein M Khaled; Wei-Ting Hwang; Brian C Baumann Journal: JAMA Surg Date: 2018-01-17 Impact factor: 14.766
Authors: Kristen Mcalpine; Dean A Fergusson; Rodney H Breau; Luke F Reynolds; Risa Shorr; Scott C Morgan; Libni Eapen; Ilias Cagiannos; Chris Morash; Luke T Lavallée Journal: Can Urol Assoc J Date: 2018-05-28 Impact factor: 1.862
Authors: Zhoobin H Bateni; Shane M Pearce; Daniel Zainfeld; Leslie Ballas; Hooman Djaladat; Anne K Schuckman; Siamak Daneshmand Journal: Eur Urol Oncol Date: 2018-12-19
Authors: Brian C Baumann; Paul Sargos; Libni J Eapen; Jason A Efstathiou; Ananya Choudhury; Amit Bahl; Vedang Murthy; Leslie K Ballas; Valérie Fonteyne; Pierre M Richaud; Mohamed S Zaghloul; John P Christodouleas Journal: Bladder Cancer Date: 2017-01-27